The Dark Side of Hydralazine Misuse Leading to ANCA-Associated Vasculitis: A Case Report Series and Literature Review (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #PUB136; "Induction with cyclophosphamide and glucocorticoids was complicated by E. coli bacteremia and pancytopenia, necessitating transition to rituximab...Hydralazine was discontinued, and the patient was treated with plasmapheresis, rituximab, glucocorticoids, and avacopan maintenance...Different outcomes, including ESRD and partial recovery, emphasize the importance of early recognition, adequate biopsy sampling, and prompt immunosuppressive therapy. Hydralazine should be reserved as a last-line antihypertensive to prevent serious complications and potentially irreversible kidney damage."
Case report • Clinical • Review • ANCA Vasculitis • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis
|
|
Amanda Nicole Coburn; Liliya Adzhieva; Andrea Bergano; Sayed Husain; Alan P. Lim; Clarissa Araujo Cassol
|